EU Reviews Safety of Redness-Reducing Skincare Ingredient
Shoppers using eye creams and serums for dark circles and redness should note that the ingredient's safety review is only preliminary so far.
Updated on Nov. 5, 2026 in Beauty

The European Union's Scientific Committee on Consumer Safety (SCCS) has published a preliminary opinion on the safety of phytonadione epoxide, an oxidised form of vitamin K1 used in cosmetics. The opinion follows a European Commission call for data and a June 2026 mandate asking the committee to assess the ingredient, which is mainly used as a skin conditioning agent in eye creams and serums for sensitive or redness-prone skin.
Why it matters
Phytonadione epoxide is used in products marketed to reduce the appearance of dark circles and redness, so a regulatory safety review directly shapes what consumers can buy in the European market. Because the opinion is preliminary, final conclusions on use levels and permitted products remain pending.
The assessment is a preliminary opinion from the SCCS, based on data gathered through a European Commission call for data that ran from May 2025 to May 2026. The source does not report specific study sizes, safety endpoints or findings, so the strength of the evidence base cannot be characterised beyond the preliminary status.
The players
Scientific Committee on Consumer Safety (SCCS)
The European Union advisory body that evaluates the safety of ingredients used in cosmetic products sold in the EU.
European Commission
The executive arm of the European Union, which set the mandate and ran the call for data that prompted the safety assessment.
The details
Phytonadione epoxide is formed when the naphthoquinone ring of phytonadione, a form of vitamin K1, is epoxidised, producing an oxidised derivative. In cosmetics it works mainly as a skin conditioning agent and is reported to help reduce the appearance of dark circles and redness. The ingredient appears in eye contour creams, anti-ageing serums and formulations for sensitive or redness-prone skin, which is why the Commission asked the SCCS to examine its safety.
Timeline
May 2025 to May 2026: European Commission runs its call for data on phytonadione epoxide.
June 2026: The SCCS accepts the Commission's mandate to assess the ingredient's safety.
5 November 2026: The SCCS publishes its preliminary opinion.
Health Landscape
Cosmetic ingredient safety in the EU is assessed case by case by the SCCS under the Cosmetics Regulation (EC) No 1223/2009, with opinions informing whether ingredients remain permitted. This preliminary opinion on phytonadione epoxide places a vitamin K1 derivative within that ongoing review of skin-applied active-style ingredients.
If you use eye creams or serums marketed for dark circles or redness, this review is worth noting, since the ingredient's safety is still being assessed. Anyone with sensitive or redness-prone skin who has questions about a product containing phytonadione epoxide may want to raise them with a dermatologist or pharmacist.
The takeaway
A preliminary opinion is an early checkpoint, not a final verdict, so the SCCS's conclusions on phytonadione epoxide are still to come. Readers managing sensitive skin can keep an eye on the committee's final opinion before drawing firm conclusions about this ingredient.
Further reading
For broader context on how skincare ingredients are judged, explore our Beauty coverage.
Source note: This article includes information reported by CosmeticOBS.


